Nordic Nanovector and AREVA Med, the AREVA medical subsidiary developing lead-212 (212Pb) based cancer therapies, have entered into a collaboration agreement to investigate the potential of a 212Pb-conjugated anti-CD37 antibody for the treatment of leukaemias.
Leukemias are orphan diseases with a